Evidence map›Paper›PMID 38507991›Full record

ArticleOral oncology2024

Prognostic value of tumor volume doubling time in lung-metastatic adenoid cystic carcinoma.

Eduardo A Dal Lago, Luana G Sousa, Zixi Yang, Camilla O Hoff, Flavia Bonini, Matthew Sawyer, Kaiwen Wang, Whitney Lewis, Kareem A Wahid, Ehab Y Hanna and 5 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oral oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Eduardo A Dal LagoDepartment of Thoracic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Luana G SousaDepartment of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Zixi YangBiostatistics Department, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Camilla O HoffDepartment of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Flavia BoniniDepartment of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Matthew SawyerDepartment of Medicine, Baylor College of Medicine, Houston, TX, USA.
Kaiwen WangDepartment of Pharmacy, The University of Texas Health Science Center at Houston, TX, USA.
Whitney LewisDepartment of Pharmacy, The University of Texas Health Science Center at Houston, TX, USA.
Kareem A WahidRadiation Oncology, The University of Texas Health Science Center at Houston, TX, USA.
Ehab Y HannaDepartment of Head and Neck Surgery, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Adel El-NaggarDepartment of Pathology, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Clifton D FullerRadiation Oncology, The University of Texas Health Science Center at Houston, TX, USA.
Suprateek KunduDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Myrna GodoyDepartment of Thoracic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Renata FerrarottoDepartment of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: rferrarotto@mdanderson.org.
The University of Texas Health Science Center at Houston · USThe University of Texas MD Anderson Cancer Center · USBaylor College of Medicine · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Image Guided Cancer Therapy Training ProgramT32CA261856 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Kristy Brock, Clifton David Fuller · 2022 to 2026
$1.2M
NCI NIH HHS P30 CA016672NCI NIH HHS T32 CA261856
6 · The paper itself

Abstract

objectivesLung metastases in adenoid cystic carcinoma (ACC) usually have indolent growth and the optimal timing to start systemic therapy is not established. We assessed ACC lung metastasis tumor growth dynamics and compared the prognostic value of time to progression (TTP) and tumor volume doubling time (TVDT).

methodsThe study included ACC patients with ≥1 pulmonary metastasis (≥5 mm) and at least 2 chest computed tomography scans. Radiology assessment was performed from the first scan showing metastasis until treatment initiation or death. Up to 5 lung nodules per patient were segmented for TVDT calculation. To assess tumor growth rate (TGR), the correlation coefficient (r) and coefficient of determination (R

resultsThe study included 75 patients. Sixty-seven patients (89%) had lung-only metastasis on first CT scan. The TGR was overall constant (median R

conclusionMost ACC lung metastases have a constant TGR. TVDT may be a better prognostic indicator than TTP in lung-metastatic ACC. TVDT can be estimated by single longitudinal measurement in clinical practice.

Indexed as

Carcinoma, Adenoid CysticLung NeoplasmsHumansLungPrognosisRetrospective StudiesTime FactorsTumor BurdenAdenoid cystic carcinomaNeoplasm metastasisProgression-free survivalResponse evaluation criteria in solid tumorsTumor burden

Identifiers

PMID38507991
PMCPMC11195296
OpenAlexW4392955010

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.